The purpose of the study is to determine if Eloralintide is more effective than a placebo at helping to change body weight. During the study, participants will be assigned to receive either the active medication or a placebo once every week. The process is double-blind, meaning that neither the participants nor the researchers know who is receiving the actual drug or the inactive substance until the study is complete. Participants will be monitored over a period of time to observe changes in weight and to ensure safety.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

The purpose of the study is to find out if ponsegromab can help people gain body weight, improve appetite-related symptoms, and see if it is safe to use. During the study, participants will receive either ponsegromab or placebo along with their regular chemotherapy treatment. The study will measure changes in body weight, appetite symptoms, physical activity levels, and body composition using CT scan or MRI imaging. The study will also look at how the cancer responds to treatment and track overall survival and quality of life measures. Participants will be monitored for side effects and any changes in their health throughout the study period.

The study will last for several years and includes regular visits where measurements will be taken at different time points, with an important assessment at week 12. The study also includes an open-label extension phase where participants may continue to receive ponsegromab. Throughout the study, doctors will check body weight, muscle mass, fat tissue, physical activity, fatigue levels, and overall well-being using questionnaires and physical measurements.

The main purpose of this study is to compare how long people live when treated with the investigational medicine compared to docetaxel. The study will look at this in all people whose tumors have PD-L1 levels of at least one percent, and also specifically in those whose tumors have PD-L1 levels of fifty percent or higher. People taking part will be randomly assigned to receive either the investigational medicine or docetaxel. The study will also look at other things like how well the tumors respond to treatment, how long any response lasts, and what side effects occur with each treatment.

During the study, participants will receive their assigned treatment for up to sixty months. Those receiving the investigational medicine will get it at a dose based on their body weight, while those receiving docetaxel will get it at a dose based on their body surface area. The study team will regularly check how the cancer is responding to treatment and monitor for any side effects. Participants will also be asked about their quality of life and any symptoms they are experiencing. Blood samples will be taken from those receiving the investigational medicine to measure drug levels in the body and to check for immune responses to the medicine. Tumor tissue samples will also be collected for testing to help understand how the treatments work.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The treatment will involve taking PF-07248144 tablets by mouth along with fulvestrant injections into the muscle. Some patients will receive this combination, while others will receive different standard treatments such as everolimus or exemestane. The purpose is to determine if the combination of PF-07248144 and fulvestrant works better than currently available treatments in stopping the cancer from growing.

The study will last for up to 24 months. During this time, patients will have regular check-ups to monitor their health and see how well the treatment is working. Doctors will use special scans to measure if tumors are shrinking, staying the same size, or growing. They will also keep track of any side effects that patients may experience during the treatment.

The main purpose of this study is to determine if Verekitug can reduce the number of COPD flare-ups (also called exacerbations) that patients experience. During these flare-ups, COPD symptoms become worse than usual, often requiring additional medical treatment. The study will involve patients who have already experienced such flare-ups in the past and are currently using standard COPD medications.

The treatment period will last for 108 weeks (approximately two years). Throughout the study, participants will receive regular injections of either Verekitug or placebo, while continuing their usual COPD medications. The study will monitor how well participants breathe, their quality of life, and any side effects they may experience. Blood samples will be taken to measure how the medication works in the body.

The study will test whether a medication called vicadrostat (BI 690517) when used in combination with another medication called empagliflozin is better than empagliflozin alone (with placebo) for treating heart failure. The purpose of the study is to determine if this combination therapy can reduce the occurrence of cardiovascular death, hospitalizations for heart failure, or urgent heart failure visits.

Participants in this study will be randomly assigned to receive either the combination of vicadrostat and empagliflozin or empagliflozin with placebo. The study will track outcomes such as cardiovascular events and measure heart failure symptoms using a questionnaire. This is a double-blind study, which means neither the participants nor the researchers will know which treatment each participant is receiving during the study.

The purpose of the study is to see if the combination of Sigvotatug vedotin and pembrolizumab is better at treating NSCLC compared to using pembrolizumab alone. Participants in the study will be randomly assigned to receive either the combination treatment or pembrolizumab by itself. The study will monitor how long patients live and how long they remain free from cancer progression. The trial will also look at the safety of the treatments and any side effects that may occur.

Participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, with regular check-ups to monitor the participants’ health and the effectiveness of the treatment. The trial aims to provide valuable information that could improve treatment options for people with advanced non-small cell lung cancer.

The purpose of the study is to evaluate how well participants tolerate the medication over an extended period. Participants who have already shown a response to the treatment in previous trials will continue to take zasocitinib in capsule form. The study will last for up to 108 weeks, during which time participants will be monitored for any side effects or changes in their health. Some participants will receive a placebo, which is a substance with no active medication, to compare the effects of the actual drug.

Throughout the study, participants will have regular check-ups to assess their health, including monitoring vital signs and conducting laboratory tests. The study aims to gather information on the long-term effects of zasocitinib to better understand its safety and effectiveness in treating Ulcerative Colitis and Crohn’s Disease.

The purpose of the study is to assess whether RO7790121 can help patients achieve clinical remission, which means a significant reduction in disease activity, and an endoscopic response, which refers to visible improvements in the digestive tract as seen through an endoscope. Participants in the study will receive either the treatment or a placebo, and their progress will be monitored over time to see how well the treatment works in reducing symptoms and improving their condition.

Throughout the study, researchers will track various outcomes, such as the overall change in symptoms, the severity of symptoms, and the general well-being of participants. They will also monitor any adverse events, which are unwanted effects that might occur during the trial. The study aims to provide valuable information on the potential benefits and risks of using RO7790121 for treating Crohn’s Disease, helping to improve future treatment options for those affected by this condition.

The purpose of the study is to evaluate the safety of BI 456906 in terms of heart health compared to a placebo. Participants will receive either the treatment or a placebo and will be monitored over time to see if there are any differences in the occurrence of heart-related events such as heart attacks, strokes, or heart failure. The study will also look at changes in body weight, blood pressure, and other health markers over a period of time.

Participants in the study will be followed for several weeks, with regular check-ups to monitor their health and any changes that occur. The study aims to provide valuable information on whether BI 456906 is a safe and effective treatment option for people with obesity and related health conditions. The results could help improve the management of obesity and its complications in the future.

The purpose of the study is to compare the new treatment combination to other therapies chosen by the study doctors. Participants will be randomly assigned to receive either the new treatment or one of the other therapies. The study will last for up to 24 months, during which participants will receive regular treatments and check-ups to monitor their health and the progress of their cancer. The study aims to see if the new treatment can help delay the progression of the disease.

Participants in the study will include adults over the age of 18 who have previously been treated with a type of medication known as a CDK 4/6 inhibitor, which is used to slow down the growth of cancer cells. The study will also look at how the new treatment affects overall survival, the response of the cancer to treatment, and the quality of life of participants. This research is important for finding new ways to manage and treat advanced breast cancer, offering hope for improved outcomes for patients in the future.

The purpose of the study is to evaluate whether Zasocitinib can help achieve clinical remission, which means reducing the symptoms of ulcerative colitis, by the 12th week of treatment. Participants in the study will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The trial will last for a total of 52 weeks, with the main focus on the first 12 weeks to assess the initial response to the treatment.

Throughout the study, participants will undergo regular check-ups and assessments to monitor their health and the effects of the treatment. These assessments will include evaluating symptoms such as stool frequency and rectal bleeding, as well as conducting endoscopic examinations to observe the condition of the colon. The study aims to provide valuable information on the potential benefits of Zasocitinib for individuals suffering from ulcerative colitis, with the hope of improving their quality of life.

The trial investigates whether using semaglutide along with a lower dose of insulin can control blood sugar levels just as effectively as using a higher dose of insulin by itself. Both medications are given through subcutaneous injection (under the skin) using pre-filled injection pens. The semaglutide is given once weekly, while insulin glargine is administered once daily.

The study lasts for 40 weeks and involves measuring changes in HbA1c (a measure of average blood sugar levels over the past 2-3 months). Participants will receive either a combination of semaglutide with reduced insulin glargine or insulin glargine alone. The study also looks at changes in body weight and how satisfied participants are with their treatment.

The purpose of this research is to assess how well remibrutinib works over an extended period in patients who have already participated in previous studies of this medication. During the study, patients who showed improvement in their symptoms will either continue taking remibrutinib or switch to placebo. The researchers will monitor how long it takes for symptoms to return, if they do.

Throughout the study, participants may also receive other common treatments for their condition, including antihistamines (medications that reduce allergic symptoms) and corticosteroids (medications that reduce inflammation). The study will track any side effects that occur during the treatment period. The total duration of treatment may last up to 160 weeks, depending on the participant’s response to the medication.

The purpose of this study is to see how effective Plozasiran is at reducing triglyceride levels in people with severe hypertriglyceridemia. Participants in the study will receive either Plozasiran or a placebo and will be monitored over a period of 12 months. During this time, the study will measure changes in triglyceride levels and monitor for any side effects. The goal is to determine if Plozasiran can significantly lower triglyceride levels compared to the placebo.

Participants will receive regular injections and attend scheduled visits to track their progress. The study aims to provide valuable information on the safety and effectiveness of Plozasiran, which could lead to new treatment options for people with severe hypertriglyceridemia. This research is important for understanding how to better manage this condition and improve patient outcomes.

The purpose of the study is to assess how effective and safe Plozasiran is in reducing fasting triglyceride levels in adults with Hypertriglyceridemia. Participants in the study will receive either the Plozasiran injection or a placebo. The study will last for about 12 months, during which participants will have regular check-ups to monitor their triglyceride levels and overall health.

This study is conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure the results are unbiased. The main goal is to see if Plozasiran can significantly lower triglyceride levels compared to the placebo, and to determine how many participants achieve a healthy triglyceride level by the end of the study.

The treatment involves receiving either Lutikizumab or placebo through subcutaneous injection (an injection under the skin). The medication being tested is a biotechnology product that aims to reduce the signs and symptoms of moderate to severe Hidradenitis Suppurativa. The study will assess how well the treatment works in both adults and adolescents who have had inadequate results with previous treatments.

The study will measure several aspects of the condition, including reduction in the number of inflammatory bumps and draining wounds, improvement in pain levels, and changes in quality of life. The treatment period will last for several months to properly evaluate the medication’s effectiveness. Throughout the study, participants will be closely monitored to ensure their safety and to track their response to the treatment.

Participants in the study will receive either XXB750 or a placebo over a period of 16 weeks. The study aims to find the best dose of XXB750 that can help reduce the levels of NT-proBNP, which is a marker used to assess heart failure severity. Patients will continue to receive their standard heart failure treatments, such as ACE inhibitors or ARBs, which are common medications used to manage heart failure symptoms.

The trial will monitor changes in NT-proBNP levels and assess any side effects or changes in health during the study period. This research is important to determine if XXB750 can be a beneficial addition to existing heart failure treatments, potentially improving the quality of life for those affected by this condition.

The purpose of the study is to evaluate how well the new combination inhaler improves lung function and reduces asthma attacks compared to the other treatments. Participants in the study will use the inhalers over a period of 24 to 52 weeks. During this time, they will visit the study center regularly for check-ups and assessments. The study will help determine if the new inhaler is more effective in managing asthma symptoms and preventing severe asthma attacks.

In addition to the inhalers, some participants may also use other medications like Salbutamol, which is a fast-acting inhaler used for quick relief of asthma symptoms, and Prednisolone, a tablet used to treat severe asthma attacks. The study aims to provide valuable information on the safety and effectiveness of the new inhaler combination for people with severe asthma.

The research aims to show how well ozanimod works compared to placebo in maintaining disease remission (a state where symptoms are minimal or absent) and improving the appearance of the intestinal lining when viewed through medical examination. The medication will be given as hard capsules that patients take by mouth. Some participants will receive ozanimod while others will receive placebo capsules that look identical to the real medication.

During the study, participants will be monitored for about one year to assess how well the treatment maintains control of their disease symptoms. The study will track various aspects of the disease, including stomach pain, bowel movements, and the condition of the intestinal lining. The maximum daily dose of ozanimod used in the study is 0.92 mg.

The study aims to determine if ponsegromab can help patients maintain or regain body weight compared to placebo. The medication is given as a subcutaneous injection, which means it is administered under the skin. The treatment period lasts for 12 months, during which patients receive either ponsegromab or a placebo.

During the study, researchers will monitor changes in body weight and physical activity. They will also track how well patients can move around and perform daily activities. The study includes the use of special sensors that measure movement and walking speed. Patients will also be asked about their appetite, feelings of nausea, and energy levels. Throughout the study, doctors will closely monitor the safety of the treatment by checking for any side effects.

The study aims to determine if evolocumab can reduce the risk of death from coronary heart disease, heart attacks, and strokes in people receiving standard cholesterol-lowering therapy. The medication is given as an injection under the skin using a pre-filled pen that contains 140 mg of evolocumab.

During the study, participants will receive either evolocumab injections or placebo injections. The treatment period lasts for 72 weeks, during which participants will continue their usual cholesterol-lowering medications. The study will track various heart-related health events, including arterial revascularization (procedures to restore blood flow in blocked arteries) and death from heart-related causes.

Participants in the study will receive Ozanimod and will be monitored over a period to observe how their symptoms change. The study will look at various aspects, such as the reduction in abdominal pain and stool frequency, and improvements in the condition of the digestive tract. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Ozanimod.

The study is designed to gather information over several years, providing insights into how Ozanimod can help manage Crohn’s Disease in the long term. Participants will be regularly assessed to track their progress and any changes in their condition. This research is important for developing better treatments for those living with Crohn’s Disease.

The purpose of the study is to assess the safety and effectiveness of PF-07220060 in treating these advanced cancers. Participants will receive the medication in tablet form, taken by mouth, and in some cases, it will be combined with other cancer treatments. The study will also explore how the body processes the medication and how it affects the tumors. Some participants will receive a placebo, which is a substance with no active medication, to help compare the effects of the treatment.

The study will be conducted in different parts, each focusing on specific types of cancer and treatment combinations. Participants will be monitored for safety and any side effects, and the study will help determine the best dose of PF-07220060 to use in future research. The trial is expected to continue until 2026, with the goal of finding new and effective ways to treat advanced solid tumors.

The purpose of this study is to evaluate how effective and safe Mirikizumab is over an extended period. Participants in the study will receive Mirikizumab and will be monitored to see how well the medication works in reducing the symptoms of Crohn’s Disease. The study will also assess the safety of the medication to ensure it is well-tolerated by those taking it.

Throughout the study, participants will receive regular injections of Mirikizumab and will have scheduled visits with healthcare professionals to track their progress. The study aims to provide valuable information on the long-term use of Mirikizumab for managing Crohn’s Disease, helping to improve treatment options for those affected by this condition.

Participants in the study will receive either Risankizumab or a placebo. The study is divided into several parts. In the first part, the focus is on comparing Risankizumab with a placebo to see how well it works in maintaining the health of participants over a period of time. In the second part, the study will look at two different ways of adjusting the dose of Risankizumab to see which method is more effective. The third part of the study will continue to monitor the long-term safety of Risankizumab in participants who have completed the earlier parts of the study or who were unable to complete the final examination due to external factors like the COVID-19 pandemic or geopolitical issues.

The study will last for a total of 52 weeks, during which participants will be monitored for any changes in their condition. The goal is to see if Risankizumab can help maintain remission, which means the symptoms of Ulcerative Colitis are reduced or disappear. The study will also look at other factors like improvements in the lining of the intestine and overall quality of life. Participants will be closely observed to ensure their safety throughout the study.

Participants in the study will be those who have been recently hospitalized with heart failure and have a certain level of heart function, measured by something called the ejection fraction. This is a percentage that shows how well the heart is pumping blood. The study will involve taking the medication or placebo for a period of time, and researchers will monitor the participants for any heart-related events or changes in their condition.

The study aims to gather information on the effectiveness and safety of finerenone in managing heart failure symptoms and improving survival rates. By comparing the outcomes of those taking finerenone with those taking a placebo, researchers hope to better understand the potential benefits of this treatment for patients with heart failure.

The study will test inclisiran, given as an injection under the skin, against placebo while participants continue taking their usual cholesterol-lowering medications. These medications include either atorvastatin (40 mg daily) or rosuvastatin (20 mg or more daily), which belong to a group of drugs called statins that help lower cholesterol levels in the blood.

During the study, which will last for 72 months, participants will receive regular injections of either inclisiran or placebo along with their daily statin medication. The researchers will monitor participants to see if the combination of treatments helps prevent serious cardiovascular events like heart attacks and strokes.

The purpose of the study is to assess how well Zasocitinib works in reducing the symptoms of Crohn’s Disease. The study will last for a period of 52 weeks, during which participants will take the medication in capsule form. The main goal is to see if the medication can help achieve an improvement in the condition by Week 12. Participants will undergo regular check-ups and assessments to monitor their progress and any changes in their symptoms.

Throughout the study, participants will be closely monitored to ensure their safety and to gather information on how the medication affects their health. The study aims to provide valuable insights into the potential benefits of Zasocitinib for individuals with moderately to severely active Crohn’s Disease, contributing to the development of more effective treatments for this challenging condition.

Participants in the study will receive either the medication upadacitinib, which is a Janus kinase (Jak) 1 inhibitor, or a placebo, along with topical corticosteroids. Topical corticosteroids are creams or ointments applied directly to the skin to reduce inflammation and itching. The study will last for several weeks, during which the participants’ skin condition will be monitored to see if there is an improvement in their eczema symptoms.

The goal of the study is to determine if the combination of upadacitinib and topical corticosteroids can effectively reduce the severity of eczema symptoms and improve the quality of life for those affected by this condition. The study will also assess the long-term safety of using upadacitinib over a period of up to 10 years. Participants will be regularly evaluated to track their progress and any changes in their condition.

Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of time, during which participants will take the medication or placebo and attend regular check-ups to monitor their condition and any changes in their symptoms. The main goal is to see if there is a significant reduction in the number of painful lumps and other symptoms associated with Hidradenitis Suppurativa after 16 weeks of treatment.

Throughout the study, participants will be asked to report on their skin condition, including any changes in pain levels and quality of life. The study aims to provide valuable information on whether Upadacitinib can be a beneficial treatment option for those suffering from this challenging skin condition. The trial is expected to continue until 2027, with recruitment starting in late 2023.

The purpose of this study is to evaluate how safe and effective Upadacitinib is over a long period. Participants in the study will take Upadacitinib in the form of a modified-release tablet, which means the medication is designed to be released slowly in the body. The study will also include a placebo group, which means some participants will receive a tablet that does not contain the active medication. This helps researchers compare the effects of the medication against no treatment.

Throughout the study, participants will be monitored regularly to assess any side effects and to see how well the medication is working in managing their Ulcerative Colitis symptoms. The study is designed to last for several years, allowing researchers to gather comprehensive data on the long-term use of Upadacitinib. Participants will have regular check-ups and assessments to ensure their safety and to track the progress of their condition.

The purpose of the study is to evaluate whether nipocalimab is more effective than a placebo in reducing the risk of severe FNAIT. Participants in the study will receive either nipocalimab or a placebo, and the study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. The study will follow the participants throughout their pregnancy and monitor the health of the baby up to the first week after birth. This will help determine if nipocalimab can safely and effectively reduce the risk of complications associated with FNAIT.

Throughout the study, the health of both the mother and the baby will be closely monitored. This includes regular check-ups and assessments to ensure the safety and well-being of both. The study aims to provide valuable information on the potential benefits of nipocalimab in managing FNAIT and improving outcomes for at-risk pregnancies. Participants will be contributing to important research that could lead to better treatment options for this condition in the future.

The purpose of the study is to evaluate the effectiveness and safety of Risankizumab compared to Ustekinumab in adults with moderate to severe Crohn’s Disease who have not responded well to previous treatments known as anti-TNF therapies. The study is divided into two parts. In the first part, participants will receive either Risankizumab or Ustekinumab for 48 weeks. The second part will focus on the long-term safety of Risankizumab for up to 220 weeks for those who completed the first part. There is also a Continuous Treatment Extension to ensure ongoing care with Risankizumab until it becomes commercially available or participants can access it locally.

Participants will be monitored for clinical remission, which means a significant reduction in symptoms, and endoscopic remission, which involves healing of the digestive tract as seen through a camera. The study aims to determine if Risankizumab is as effective or more effective than Ustekinumab in achieving these outcomes. The trial will also assess the ability to maintain remission without the use of steroids, which are often used to control inflammation. The study is expected to continue until 2027.

Participants in the study will receive either Abelacimab or a placebo, which is a substance that looks like the treatment but has no active ingredients. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will take place over a period of time, during which participants will be monitored for any occurrences of stroke or other related health events.

The trial aims to provide valuable information on the safety and effectiveness of Abelacimab for patients with atrial fibrillation who are at high risk and cannot use standard oral anticoagulation therapy. By participating in this study, researchers hope to find a new treatment option that could potentially benefit many people with this heart condition.

Participants in the study will receive either Milvexian, a placebo, or other medications such as Acetylsalicylic Acid (commonly known as aspirin) and Clopidogrel, which are standard treatments for preventing blood clots. Milvexian is taken as a film-coated tablet, and the study will compare its effectiveness and safety against these other treatments. The trial will be conducted over a period of several weeks, during which participants will be monitored for any occurrences of ischemic strokes or other related health events.

The purpose of this study is to explore new ways to prevent strokes and improve the safety and effectiveness of treatments for individuals at high risk of stroke. By participating in this trial, researchers hope to gather valuable information that could lead to better prevention strategies for stroke patients in the future.

The purpose of the study is to determine if milvexian can effectively lower the risk of major adverse cardiovascular events, such as heart attacks, strokes, or cardiovascular-related deaths, when added to the usual care. Participants in the study will be randomly assigned to receive either milvexian or a placebo, and they will continue their regular heart medications. The study will last for a period of up to 48 weeks, during which participants will take the study medication orally in the form of film-coated tablets.

Throughout the study, participants will be monitored for any heart-related events and overall health. The goal is to see if milvexian can provide additional protection against serious heart problems compared to the placebo. This research aims to improve the understanding of how to better prevent recurrent cardiovascular events in patients who have recently suffered from a heart attack.